It’s well within Anthropic’s rights to compete in any market they choose.
What’s funny, in this instance, are the number of Pharma companies, who through their unchecked use of Anthropic, are driving revenues into what they think is a model provider but is in fact a competitor lurking in the shadows thereby accelerating their own demise.
I suspect any end market with reasonable ROCE that could be AI accelerated is on the table.
If I were them, I’d probably do the same.


















